Search Results

M2GEN today announced it is rebranding, changing the company’s name to Aster Insights™.

M2GEN , an oncology-focused health informatics solutions company, today announced its participation as a presenter, exhibitor, and research partner at the American Association for Cancer Research (AACR) Annual Meeting April 14-19, 2023.

M2GEN, a bioinformatics company accelerating discoveries in oncology research through industry-leading data and analytics, today announced the appointment of Kyle Dunn to its executive team as Chief Revenue Officer.

M2GEN today announced the appointment of Melissa Honour, MPH, to its executive leadership team as Chief Product Officer.

M2GEN will utilize Microsoft technologies to power its data and analytics platform.

M2GEN announced today that it has entered into an agreement with Discovery Life Sciences, a global leader in biospecimen solutions, genomic, cell, and immunohistochemistry (IHC) services, to provide M2GEN’s recently launched oncology-focused bioinformatics support services.

M2GEN today announced a significant new investment by Clayton, Dubilier & Rice (“CD&R”) funds, the Merck Global Health Innovation Fund (“Merck GHI”), and McKesson Ventures to recapitalize M2GEN, a leading oncology data and informatics platform focused on transforming cancer care, in partnership with its existing shareholders

M2GEN announced today the launch of its oncology-focused Bioinformatics Support Services. Leveraging the results and knowledge gained from the ORIEN Avatar® Program, an extensive, unique and ever-growing oncology clinico-genomics dataset, the M2GEN Bioinformatics team provides bioinformatics support services adhering to best-in-class standards.

M2GEN, an oncology-focused health informatics solutions company with the mission to help patients access the best treatment options by leveraging their clinical and molecular data to accelerate the discovery, development and delivery of tailored and more personalized therapies, announced today the appointment of Chris Tunnell as Vice Pres

Bastian succeeds M2Gen Executive Chair William S. Dalton, M.D., Ph.D., who has served as interim CEO since September 2018.